K ainate receptors (KARs) are one of the three subtypes of ionotropic glutamate receptors in the CNS. These receptors are widely expressed pre-and postsynaptically throughout the brain. Thus, kainate receptor activation mediates a large variety of pre-and postsynaptic K K effects on either glutamatergic or GABAergic synaptic transmission. Although ionotropic functions for KAR have been described in multiple brain regions, there is considerable evidence from various CNS regions that KARs activation modulates GABA release through either G-protein dependent metabotropic pathway or secondary activation of G-protein coupled receptors. In the present chapter, we provide further evidence supporting that these two pathways are also involved in the modulation of GABA release in specific basal ganglia nuclei. Because of their more subtle effects on neurotransmisison regulation than other ionotropic glutamate receptors, KARs represent interesting targets for the future development of pharmacotherapy for basal ganglia diseases.
Introduction
Kainate receptors (KARs) are one of the three subtypes of ionotropic glutamate receptors in the CNS, made up of a combination of GluR5, GluR6, GluR7, KA1 and KA2 subunits. 1, 2 These receptors are widely expressed pre-and postsynaptically throughout the brain. [3] [4] [5] [6] [7] [8] [9] Cloning technology and recent development of drugs that could discriminate between kainate and AMPA receptors have led to further characterization of the pharmacological and physiological properties of KARs during the past decade. 7,8 Kainate receptors have direct actions on intrinsic cell excitability in the hippocampus 10 and modulate both glutamatergic and GABAergic synaptic transmission in a number of brain regions. 7, 8 In the hippocampus and amygdala, synaptically released glutamate from nearby excitatory synapses, can activate KARs in GABAergic terminals, thereby providing an endogeneous, physiologically relevant, mechanism mimicking the effect of exogenous KA application on inhibitory synaptic transmission. 11, 12 Although the hippocampal KARs surely deserved most attention, data from our laboratory and others have provided further evidence for a widespread pre and postsynaptic localization of KARs and their functions in many other CNS structures, including the cerebral cortex, hypothalamus, cerebellun, spinal cord and basal ganglia. 5, 7, 9, 13 In this chapter, we will provide an overview of our current understanding of the localization and function of KARs in the basal ganglia and discuss their potential relevance as novel targets for movement disorders therapy. Each basal ganglia nucleus will be discussed in turn, followed by concluding remarks related to the potential impact KARs may have in regulating basal ganglia function under normal and pathological conditions. Additional information about the basal ganglia KARs localization can also be found in a previous review. 14
Striatum
The mRNA for GluR6, GluR7 and KA2, but not GluR5 and KA1, are expressed in rat and mice striatum. 15, 16 Double in situ hybridization studies dermonstrated that most striatal projection neurons labeled for either enkephalin or substance P mRNAs co-express GluR6 mRNA. 17 The expression of KARs subunits in striatal interneurons remains to be determined. Consistent with these results, strong cellular and neuropil GluR6/7 immunoreactivity was found in the monkey striatum. 3,5 At the ultrastructural level, both GluR6/7 and KA2 are expressed in subsets of glutamatergic terminals, some of which in the sensorimotor putamen, originate from the motor cortex or the centromedian thalamic nucleus 5 (Fig. 1) . Presynaptic KARs are either extrasynaptic, away from the main release sites 
